ClinicalTrials.gg
RecruitingNCT04150614Updated Nov 5, 2026

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

A Phase 4 interventional study of Granisetron Transdermal Patch and Intravenous Dexamethasone in Nausea With Vomiting Chemotherapy-Induced, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Illinois Chicago · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2020; still recruiting 6 years 6 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies testing ondansetron in Nausea — 1 open to participants now, 1 under way, none of them phase 3. Ondansetron · Nausea.

Planned enrollment
25th of 46
90 · median 100
Started
2020
with 1 other
Phase 4
12 of 47
1 open now
Registered
41st of 47
by date

Among the 47 studies testing ondansetron in Nausea, this one is the 25th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2020, is one of 12 in phase 4, and was the 41st registered.

Nausea

646 studies on the registry are indexed under Nausea; 87 are open to participants now.

Browse Nausea studies →

Open to participants now

1 of the 47 studies testing ondansetron in Nausea is open now, in 1 country.

By country, each count listing its studies:

About ondansetron

Ondansetron: first FDA approval 1991 (ZOFRAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing ondansetron in Nausea, or all of them as a file.
02

Study summary

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.

Read the detailed description

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications. This study will be an open-label, prospective trial randomizing patients at a 1:1 ratio, to either one of two 5-hydroxytrytamine 3 (5-HT3) antagonists, transdermal granisetron or intravenous (i.v.) ondansetron, in combination with other standard, routinely administered anti-emetic drugs (dexamethasone). Rescue antiemetics will be administered at any time during the study period for vomiting or severe nausea at the request of the patients or as recommended by the attending physicians. For the granisetron treatment arm, patients will be educated and instructed to self-administer a single transdermal granisetron patch one-two days (approximately 24-48 hours) prior to start of the preparative regimen. An additional dose of transdermal granisetron will be administered 7 days after the initial granisetron dose. For the ondansetron treatment arm, patients will receive the standard dose and schedule of intravenous ondansetron that is routinely administered for each respective preparative regimen. Use of rescue medications will be assessed daily during chemotherapy, and for 7 days after the last chemotherapy drug administration (delayed phase). Nausea, vomiting, and treatment-related side effects will be documented and followed during this same time period. A quality of life questionnaire (MDASI-BMT) will be administered at Day + 7 (7 days after day of infusion). All other aspects of patient care (i.e., chemotherapy administration, supportive care, etc.) and laboratory monitoring will adhere to the routine standard of care operating procedures for stem cell transplant patients.

03

Conditions studied

  • Nausea With Vomiting Chemotherapy-Induced

Browse trials for

Keywords

  • Hematopoietic Stem Cell Transplantation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years at time of enrollment receiving either a preparative regimen and either an or allogeneic stem cell transplant.
  • No vomiting ≤ 24 hours prior to registration
  • No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.
  • No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.
  • No known to granisetron

Exclusion criteria

Exclusion Criteria:

  • Concurrent use of amifostine
  • Known to granisetron patch or ondansetron
  • Patients with a history of long syndrome or Torsade de Pointes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Arm 1

    ARM 1 -transdermal granisetron plus intravenous dexamethasone

    Drug: Granisetron Transdermal Patch · Drug: Intravenous Dexamethasone

  • Active comparator
    ARM 2

    ARM 2 -intravenous ondansetron plus intravenous dexamethasone

    Drug: Intravenous Dexamethasone · Drug: Ondansetron

Interventions

06

What researchers measure

Primary outcomes

  1. To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the acute period (0-24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Efficacy of Ondansetron and Dexamethasone versus Transdermal Granisetron and Dexamethasone in preventing chemotherapy induced nausea and vomiting during the acute period (0 - 24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Time frame: 0 hours to 24 hours post-chemotherapy

Secondary outcomes

  1. To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the delayed period (24-120 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Efficacy of Ondansetron and Dexamethasone versus Transdermal Granisetron and Dexamethasone in preventing chemotherapy induced nausea and vomiting during the delayed period (24-120 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Time frame: 24 hours to 120 hours post-chemotherapy

  2. To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the overall period (24-120 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Efficacy of Ondansetron and Dexamethasone versus Transdermal Granisetron and Dexamethasone in preventing chemotherapy induced nausea and vomiting during the overall period (24-120 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.

    Time frame: 24 hours to 120 hours post-chemotherapy

  3. To compare between the two study arms, the use of rescue anti-emetic medications (during and for 7 days after the preparative regimen) for patients receiving preparative chemotherapy and HSCT.

    Comparing the use of rescue anti-emetic medications between the two arms during and up to 7 days after the preparative regimen

    Time frame: Up to 7 days after the preparative regimen

  4. To compare between the two study arms the occurrence of CINV complete protection for patients receiving preparative chemotherapy and HSCT.

    Complete protection is defined as no emetic episode, no use of rescue medications and no nausea, during the acute, delayed, and overall phases

    Time frame: Up to 21 - 37 days post-HSCT

  5. To compare the occurrence of treatment-related adverse events (AE) between patients receiving transdermal Granisetron versus intravenous Ondansetron.

    Treatment-related adverse events (AE) will be evaluated using NCI CTCAE version 5.

    Time frame: Up to 21 - 37 days post-HSCT

  6. To compare quality of life throughout the course of HSCT between patients receiving transdermal Granisetron versus intravenous Ondansetron.

    The M.D. Anderson Symptom Inventory (MDASI) Core Items-Bone Marrow Transplant (BMT) scale will be utilized to measure quality of life at baseline, on the day of stem cell infusion, 7 days after stem cell infusion, and 21-37 days post-stem cell infusion

    Time frame: Up to 21-37 days post-HSC

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Mar 2027, 82 months after the start.

Of 28 phase 4 interventional studies under Nausea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's planned 82 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jul 2026 → Mar 2027 and completion Jul 2026 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2019
First posted
Nov 5, 2019
StartActual
May 14, 2020
Primary completionEst.
Mar 2027was Jul 2026
CompletionEst.
Mar 2028was Jul 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Mar 2027
Nov 5, 2026
Study completion
Jul 2026→Mar 2028
Nov 5, 2026
Sponsor
University of Illinois at Chicago→University of Illinois Chicago
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jul 2026→Mar 2027
    Study completion Jul 2026→Mar 2028
    Sponsor University of Illinois at Chicago→University of Illinois Chicago
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04150614
Lead sponsor
University of Illinois Chicago
Responsible party
Karen Sweiss (Clinical Assistant Professor, University of Illinois Chicago) — Principal investigator
First posted
Nov 5, 2019
Start date
May 14, 2020
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Karen Sweiss, PharmD
Contact
ksweis2@uic.edu
312-996-0875
Karen Sweiss, PharmD
principal investigator · University of Illinois Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granisetron Transdermal Patch · Ondansetron

Start the discussion